comparemela.com

Latest Breaking News On - Simonmed imaging - Page 2 : comparemela.com

Myriad Genetics, Onsite Women's Health Partner to ID Women With High Breast Cancer Risk

The program makes Myriad's hereditary breast cancer and risk assessment tools available to Onsite's pool of over 400,000 patients.

Myriad Genetics, Inc. (NASDAQ:MYGN) Q1 2023 Earnings Call Transcript

Matthew Scalo: Okay. Good afternoon, and welcome to the Myriad Genetics First Quarter 2023 Earnings Call. During the call, we will review the financial results we released today.

vimarsana © 2020. All Rights Reserved.